Press Releases from http://www.marketresearchreports.biz/analysis/308762 (1 total)
PharmaPoint: Dyslipidemia - Global Drug Forecast And Market Analysis To 2023
Summary
GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29%…
